




①  **Europäisches Patentamt**
European Patent Office
Office européen des brevets

② Publication number: **0 077 063 B1**

00 EUROPEAN PATENT SPECIFICATION

③ Date of publication of patent specification: 18.07.82
④ Application number: 82102331.1
⑤ Date of filing: 11.10.82
⑥ Int. Cl. A 61 K 45/02 // (A61K45/02, 31:365)

⑦ **Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis.**

⑧ Priority: 13.10.81 US 377035 14.06.82 US 386288	⑨ Proprietor: Eschle, Inc. 10 Gutter Mill Road Great Neck New York 11021 (US)
⑩ Date of publication of application: 20.04.82 Bulletin 82/18	⑪ Inventor: Asanul, Samuel S. 2077 Central Dr. N. East Meadow New York 11554 (US) Inventor: Rapp, Fred 2 Laurel Ridge Road Horshey Pennsylvania 17033 (US) Inventor: Miller, Daniel G. 8 Fox Run Road Saratoga New York 12858 (US)
⑫ Publication of the grant of the patent: 18.02.83 Bulletin 83/11	⑬ Representative: Vossler & Partner Siebenbrunn 4 P.O. Box 88 07 87 D-8020 München 86 (DE)
⑭ Designated Contracting States: BECH DE FR GB IT NL SE	⑮ References cited: CHEMICAL ABSTRACTS, vol. 89, no. 11, September 3, 1968, page 2285, abstract no. 62702p, Columbus, Ohio (US) T. C. MURRAY et al.: "Interferon-stimulating and in vivo antiviral effects of various synthetic nucleic polymers"

EP 0 077 063 B1

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 89(1) European patent convention).



778

Order Patent

Q 077 083

removed, but the tumor margins of the specimen showed tumor cells. The treatment would be carried out as a form of prophylactic therapy, with monitoring for recurrence.

Although the 100 day courses of daily application with an occlusive dressing are preferable in the treatment of malignant and pre-malignant skin lesions, modifications can be readily made as necessary in treatment of specific cases.

In treatment of herpes zoster

Topical application, preferably with an occlusive dressing, would be made of a pharmaceutical composition containing interferon and an antiviral nonionic surfactant, as described above. Application would be made two to three times daily until there was evidence of healing. By using the pharmaceutical composition of the present invention, pain associated with herpes zoster is alleviated because of local healing. Additionally, use of the pharmaceutical composition of the present invention in treatment of herpes zoster has been found to prevent postherpetic neuralgia.

The lesions associated with herpes zoster have been determined to heal faster than if left untreated.

In the treatment of psoriasis

Repeated courses of topical application of interferon and an antiviral nonionic surfactant in a physiologically acceptable carrier according to the present invention would be required. Psoriasis is a chronic, recurring condition, for which there is no known cure. Since large areas of the skin are often involved, a plastic occlusive dressing would preferably be used to insure absorption into the skin of the pharmaceutical composition containing human interferon and an antiviral nonionic surfactant. Additionally, since large areas may be involved and hence require treatment, a significant amount of the human interferon would be absorbed into the bloodstream. Such may have a favorable effect on the systemic aspects of psoriasis, i.e., psoriatic arthritis.

Topical administration

may be effected by applying a small amount, i.e., about 1 mg of the compositions containing human interferon and an antiviral nonionic surfactant directly to skin areas subject to the skin conditions with a cotton swab, soft brush or sponge. The quantity applied would be dependent on the size of the lesions being treated. Any quantity sufficient to cover the area of the lesions is effective.

In addition to direct application, the pharmaceutical compositions containing human interferon and an antiviral nonionic surfactant may be administered topically by various other methods. For example, the compositions may be delivered to the affected skin region in microencapsulated form. The pharmaceutical compositions may also be delivered in a foam or by spray.

As indicated hereinabove, the pharmaceutical compositions of this invention are also useful as a prophylactic for and in the treatment of *in situ* epidermal carcinoma. In this application the interferon-containing compositions would be applied directly to the cervical or genital area.

Claims

1. A pharmaceutical composition for treating herpes simplex viral infections, microbial skin infections, malignant skin lesions, pre-malignant skin lesions and/or skin lesions associated with herpes zoster or psoriasis in humans, consisting of 10^4 to 10^8 I.U. per dosage unit of a human interferon, an effective amount of an antiviral nonionic surface active agent, and a physiologically acceptable carrier for topical application.

2. The composition of Claim 1 wherein the amount of antiviral surface active agent is 0.1 to 20%, preferably 1% to 5%.

3. The composition of Claim 1 wherein the nonionic surface active agent has of least one ether or amide linkage.

4. The composition of Claim 3 wherein the nonionic surface active agent is nonylphenoxypolyethoxy ethanol, n-dodecylphenoxypolyethoxy ethanol, polyoxyethylene (10) dialyl ether, or Onyx-600 S&B.

5. The composition of Claim 4 wherein the human interferon is leukocyte interferon.

6. The composition of Claim 5 wherein the amount of human interferon is 10^4 to 10^8 I.U.

7. The composition of Claim 1 wherein said carrier is a pharmaceutically acceptable carrier and/or is essentially sterile.

8. The composition of Claim 1 wherein the carrier includes water, ethanol, polyethylene glycol, mineral oil, petrolatum, or propylene glycol.

Patentansprüche

1. Arzneimittel zur topischen Behandlung von Herpes simplex Virusinfektionen, mikrobiellen Hautinfektionen, malignen Hautgeschwülden, prä-malignen Hautgeschwülden, und/oder mit Herpes zoster oder Psoriasis einhergehenden Hauterkrankungen beim Menschen, das aus 10^4 bis 10^8 I.E. pro Dosiseinheit menschlichem Interferon, einer wirksamen Menge eines antiviralen, nicht-ionischen oberflächenaktiven Mittels und einem physiologisch verträglichen Trägerstoff besteht.